The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines some exciting ongoing clinical trials investigating CAR T-cell products in lymphoma. The ZUMA-23 trial (NCT05371093) is a Phase III trial of axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) regimens in the first-line for patients with high-risk large B-cell lymphoma (LBCL). In the setting of follicular lymphoma (FL), ZUMA-22 (NCT05371093) and LEDA (NCT05888493) are comparing axi-cel and tisagenlecleucel (tisa-cel), respectively, to SOC chemoimmunotherapy regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria and travel support: Novartis, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Autolus, Sandoz, Miltenyi, AstraZeneca.
